Revolution Medicines shares are trading higher after the company announced results for its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib. Also, all PFS and OS endpoint results are considered final.

Benzinga Newsdesk www.benzinga.com Positive 93.2%

Neg 0% Neu 0% Pos 93.2%

Comments

No comments yet. Be the first!